J Biol Chem, Vol. 274, Issue 34, 24031-24037, August 20, 1999
Cloning and Characterization of the Gene for a New Epithelial
-Defensin
GENOMIC STRUCTURE, CHROMOSOMAL LOCALIZATION, AND EVIDENCE FOR
ITS CONSTITUTIVE EXPRESSION*
Guolong
Zhang
,
Hideki
Hiraiwa§,
Hiroshi
Yasue¶,
Hua
Wu
,
Christopher R.
Ross
,
Deryl
Troyer
, and
Frank
Blecha
From the
Department of Anatomy and Physiology, Kansas
State University, Manhattan, Kansas 66506, the § Animal
Genome Program Team, Society for Technoinnovation of Agriculture,
Forestry, and Fisheries Institute, 446-1 Ippaizuka, Kamiyokoba,
Tsukuba, Ibaraki 305-0854, Japan, and the ¶ Department of Animal
Genetics and Breeding, National Institute of Animal Industry, Tsukuba,
Ibaraki 305-0901, Japan
 |
ABSTRACT |
Mammalian
-defensins are
endogenous cysteine-rich peptide antibiotics that are produced either
by epithelial cells lining the respiratory, digestive, and urogenital
tracts or by granulocytes and macrophages. A growing body of evidence
has implicated these peptides in host defense, particularly mucosal
innate immunity. We previously reported the cloning of the full-length
cDNA for a porcine
-defensin (pBD-1), which was
found to be expressed throughout the airway and oral mucosa. Here, we
provide the structural organization of the pBD-1 gene,
showing that the entire gene spans ~1.9 kilobases with two short
exons separated by a 1.5-kilobase intron. Fluorescence in
situ hybridization mapped the pBD-1 gene to porcine
chromosome 15q14-q15.1 within a region of conserved synteny to the
chromosomal locations of human and mouse
- and
-defensins. We
also provide several independent lines of evidence showing that the
pBD-1 gene is expressed constitutively during inflammation
and infection, despite its resemblance to many inducible epithelial
-defensins in amino acid sequence, genomic structure, and sites of
expression. First, stimulation of primary porcine tongue epithelial
cells with lipopolysaccharide, tumor necrosis factor-
, and
interleukin (IL)-1
failed to up-regulate the expression of
pBD-1 mRNA. Second, pBD-1 gene expression
was not enhanced in either digestive or respiratory mucosa of pigs
following a 2-day infection with Salmonella typhimurium or
Actinobacillus pleuropneumoniae. Last, direct transfection
of the pBD-1 gene promoter into NIH/3T3 cells showed no
difference in reporter gene activity in response to stimulation by
lipopolysaccharide and IL-1
. The constitutive expression of
pBD-1 in airway and oral mucosa, which is consistent with a
lack of consensus binding sites for nuclear factor-
B or NF-IL-6 in
its promoter region, suggests that it may play a surveillance role in
maintaining the steady state of microflora on mucosal surfaces.
 |
INTRODUCTION |
Mammalian defensins constitute a large family of endogenous
peptide antibiotics with broad spectrum activity against various bacteria, mycobacteria, fungi, and viruses (1-4). Upon microbial invasion, mature active defensins are released quickly by proteolytic processing from precursor peptides either in cytoplasmic granules of
most mammalian neutrophils and macrophages or in epithelial cells of
the respiratory, gastroenteric, and urogenital tracts (2-5). Killing
of bacteria by defensins appears to involve direct interactions with
target cell membranes, followed by insertion and permeabilization of
membranes by forming multimeric pores (1-4, 6-9).
All defensins are polycationic 3-5-kDa peptides and are characterized
by the presence of six conserved cysteine residues forming three
intramolecular disulfide bonds with a compact triple-stranded
-sheet
structure (6-10). Based on the positions of six cysteine residues and
linkages of the disulfide bonds, defensins are divided further into two
groups:
- and
-defensins. In contrast to most
-defensins,
which are of myeloid origin and expressed constitutively in
granulocytic leukocytes, many
-defensins are synthesized inducibly by epithelial cells during inflammation and infection (2-4, 11). Interestingly, despite a lack of similarity in nucleotide and amino
acid sequences between these two groups, all
- and
-defensin genes are clustered in close proximity on the same chromosome, as
demonstrated in humans (12-15), mice (16, 17), cattle (18, 19), and
sheep (19, 20). This finding suggests that they may have evolved from a
common ancestral defense gene by duplication (14, 15).
Several peptide antibiotics, particularly
-defensins, have been
implicated in chronic bacterial infections in cystic fibrosis patients,
where it is hypothesized that they are inactivated by the high-salt
airway surface fluid (21-25), suggesting that epithelial
-defensins
may play an important role in mucosal host defenses. Based on gene
structure, length, and homology of amino acid sequences and sites of
expression, epithelial
-defensins are classified further into two
subgroups (11, 26) (Fig. 1). The first
group contains precursor peptides of 68-69 amino acid residues, each with a relatively large gene containing an intron of >6.5
kb.1 This group includes
human
-defensin-1 (22, 27-32) and mouse
-defensin-1 (17, 33).
Besides the epithelia of respiratory and digestive tracts, kidney and
genitourinary epithelia appear to be the major expression sites. The
second group contains precursor peptides that are generally 5-6 amino
acids shorter, and each has a rather compact gene with a shorter intron
of <2 kb. Bovine tracheal antimicrobial peptide (TAP) (34-37),
lingual antimicrobial peptide (37-39), and enteric
-defensin (40)
and human BD-2 (12, 24, 41) belong to this group. They are expressed
abundantly in oral and airway epithelia. Another striking difference
between these two groups is that the
-defensins of the first group
have a constitutive expression pattern, whereas genes in the second group are expressed inducibly during inflammation and infection. Genes
for TAP-like inducible
-defensins contain several consensus recognition sites for nuclear factor (NF)-
B and NF-IL-6 in their promoter regions, which may explain their inducibility upon
inflammation and infection (12, 35, 40). However, the reliability of this classification scheme remains to be tested because significant interspecies differences exist in gene families of many peptide antibiotics (1).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 1.
Current classification of mammalian
epithelial -defensins. Based on length
and homology of amino acid sequences, gene structure, and sites of
expression, epithelial -defensins are classified into two groups
(11, 26). Group 1 contains 68-69 amino acid residues, whereas Group 2 is generally 5-6 amino acids shorter. This figure was adapted from
Ref. 26. h, human; m, mouse; s, sheep;
LAP, lingual antimicrobial peptide; EBD, enteric
-defensin.
|
|
Recently, we cloned the full-length cDNA for a porcine
-defensin
(pBD-1), which is expressed abundantly in tongue epithelia and to a lesser extent throughout the respiratory and digestive tracts
(26). It resembles many inducible epithelial
-defensins, including
bovine TAP, lingual antimicrobial peptide, and enteric
-defensin and
human BD-2 in both amino acid sequence and sites of
expression (26). Recombinant pBD-1 has potent antibacterial activity
against Escherichia coli, Salmonella typhimurium,
and Listeria monocytogenes in a salt-dependent
fashion and also is synergistic with several porcine neutrophil-derived
peptide antibiotics in killing these bacteria (42).
Here, we report the cloning, mapping, and characterization of the
pBD-1 gene. The gene mapped to Sus scrofa
chromosome 15q14-q15.1, providing the first direct evidence that
Homo sapiens chromosome 8p23, the location of human
- and
-defensin genes (12-15), corresponds to the region on S. scrofa chromosome 15 previously shown to contain a narrow portion
of H. sapiens chromosome 8 (43, 44). In contrast to the
genes for other inducible epithelial
-defensins, the
pBD-1 gene does not contain consensus binding sites in the
promoter region for either NF-
B or NF-IL-6, suggesting that it may
not be modulated by proinflammatory mediators. Indeed, we provide several lines of evidence showing that the pBD-1 gene is
expressed constitutively during inflammation and infection. To our
knowledge, this is the first example that contradicts the current
classification of epithelial
-defensins by showing that TAP-like
-defensins do not always exhibit an inducible expression pattern.
These findings also support the hypothesis that epithelial pBD-1 may
play a role in maintaining the balance of natural microflora on mucosal
surfaces under basal conditions.
 |
EXPERIMENTAL PROCEDURES |
Cloning of the pBD-1 Gene--
A two-step polymerase chain
reaction (PCR) was used to screen a porcine genomic bacterial
artificial chromosome (BAC)
library2 for BAC clones
containing the pBD-1 gene as described previously (45). Two
pairs of primers derived from the cDNA or partial genomic sequence
of pBD-1 were used: 5'-ATG AGA CTC CAC CGC CTC CTC CT-3'
(sense) and 5'-GCA GCA TTT GAC TTG GGG CAT G-3' (antisense) (product
size: 1.7 kb); and 5'-GGG TTA TGA AGT ATC CAT GTA ACC GAC-3' (sense)
and 5'-GGT CAG CTC CAC TAG GAC AGC AGA G-3' (antisense) (product size:
812 bp). Positive BAC clones were purified and digested with
BamHI or EcoRI and then subcloned into the
pBluescript II KS+ plasmid (Stratagene, La Jolla, CA) as
described (46). The subsequent clones were screened for the presence of
the pBD-1 gene by PCR amplification using the above four
primers. The positive plasmids were sequenced directly with
gene-specific primers using a 33P-labeled dideoxynucleotide
terminator cycle sequencing kit (Amersham Pharmacia Biotech).
Chromosomal Localization of the pBD-1 Gene--
Metaphase
chromosome spreads, prepared from a porcine peripheral blood
mononuclear cell culture, were subjected to fluorescence in
situ hybridization (FISH) as described previously (47, 48). Briefly, BAC DNA was labeled with biotin by nick translation (Roche Molecular Biochemicals) and hybridized to metaphase chromosome DNA.
Specific binding was detected with fluorescein isothiocyanate-labeled streptavidin and biotinylated anti-streptavidin antibody (Vector Labs,
Inc., Burlingame, CA), followed by propidium iodide staining to
simultaneously induce the R-banding. A two-color FISH was performed using elongated chromosome spreads with a biotin-labeled
pBD-1 BAC DNA and a digoxigenin-labeled BAC DNA for SW919,
which is a United States Department of Agriculture Meat Animal Research Center marker for porcine chromosome 15. After hybridization, the
probes were detected with rhodamine-labeled anti-digoxigenin antibody
(Roche Molecular Biochemicals) and fluorescein isothiocyanate-labeled streptavidin/biotinylated anti-streptavidin antibody, followed by
4,6-diamidino-2-phenylindole staining to visualize chromosomes.
Primer Extension of pBD-1 mRNA--
Poly(A)+
mRNA from porcine tongue epithelial cells was isolated using
oligo(dT)30-containing Oligotex latex beads (QIAGEN Inc., Chatsworth, CA), annealed with the 5'-end-labeled primer 5'-CTG GCA CAG
GTA ACA GGA CCA TGA GG-3', and extended with avian myeloblastosis virus
reverse transcriptase (Promega, Madison, WI) as described previously
(49). The extension product was heat-denatured and analyzed on a
urea-6% polyacrylamide DNA sequencing gel and then subjected to
autoradiography. A dideoxynucleotide termination DNA sequence ladder
was used as the size standard.
Culture and Stimulation of Porcine Tongue Epithelial
Cells--
Because pBD-1 mRNA could be detected easily
by Northern blot analysis in porcine tongue epithelial cells, primary
tongue epithelia were scraped from the filiform papillae of the dorsal
side of tongues of 6-8-week-old healthy outbred pigs and used for
stimulation. All experiments were conducted under stringent LPS-free
conditions. Low-endotoxin fetal bovine serum was used (Hyclone
Laboratories, Logan, UT), and cell culture media were below 0.03 endotoxin units/ml (Limulus amebocyte lysate assay, Sigma).
Cells were washed three times with serum-free RPMI 1640 medium and
plated in six-well tissue culture plates in complete RPMI 1640 medium
(RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum,
100 units/ml penicillin, and 100 µg/ml streptomycin). After 3 h
of incubation at 37 °C and 5% CO2, cells were
stimulated with LPS (0.1 and 1 µg/ml) from S. typhimurium
(Sigma), 10 ng/ml recombinant porcine TNF-
(Endogen, Inc., Woburn,
MA), 10 ng/ml recombinant human IL-1
(R&D Systems, Minneapolis, MN),
or a combination of the three proinflammatory agents for another 9 or
16 h. Cells were then harvested for RNA isolation and Northern analysis.
Infection of Pigs with S. typhimurium and Actinobacillus
pleuropneumoniae--
Healthy outbred pigs at 6-8 weeks of age were
obtained from the Kansas State University Swine Research Unit and
housed in an environmentally controlled isolation facility. Infection
studies began 1 week after pigs were acclimated to their new
environment. Clinical signs for bacterial infections were monitored
during the experiments. For S. typhimurium infection, pigs
were gavaged with 109 colony-forming units of bacteria
suspended in growth medium. Samples of jejunum and colon were collected
at 12, 24, and 48 h post-infection immediately following
euthanasia using three to four pigs/time point. Four control pigs were
gavaged with growth medium and euthanized at 6 h. Epithelial
tissues were scraped from the collected intestinal samples and used for
RNA isolation. For A. pleuropneumoniae infection, pigs were
challenged intranasally either with 5 × 108
colony-forming units of bacteria in growth medium or with medium alone
using four pigs/group. Tracheal epithelial tissues were collected
48 h post-infection and used for isolation of RNA.
Reverse Transcriptase-PCR--
Total RNA was extracted using
Trizol reagent (Life Technologies, Inc.) following the manufacturer's
instructions. One µg of each RNA sample was used to perform
first-strand cDNA synthesis in a total volume of 20 µl with 25 units of Moloney murine leukemia virus reverse transcriptase
(Perkin-Elmer) and 10 units of RNase inhibitor (Perkin-Elmer) as
described previously (28). One-tenth of each resulting cDNA was
used in the subsequent PCR in a 25-µl reaction volume with a 0.1 µM concentration of each sense and antisense primer and
1.25 units of platinum Taq DNA polymerase (Life
Technologies, Inc.). The primers for amplification of pBD-1 cDNA were 5'-ATG AGA CTC CAC CGC CTC CTC CT-3' (sense) and 5'-GCA GCA TTT GAC TTG GGG CAT G-3' (antisense). The primers for the housekeeping gene
-actin were 5'-GGA CTT CGA GCA GGA GAT GG-3' (sense) and 5'-GCA CCG TGT TGG CGT AGA GG-3' (antisense). The PCR
program was 2 min at 94 °C, followed by 26 (for pBD-1) or 16 (for
-actin) cycles of 30 s at 60 °C, 30 s at
72 °C, and 30 s at 94 °C, followed by a final extension for
7 min at 72 °C.
Southern and Northern Blot Analyses--
For Southern analysis,
10 µg of porcine genomic or BAC DNA or 10 µl of PCR products were
separated on agarose gels, followed by denaturation and overnight
capillary transfer onto positively charged nylon membranes (Roche
Molecular Biochemicals). For Northern analysis, 10 µg of total RNA
from tongue epithelial cells were denatured and fractionated on
formaldehyde-containing 1.2% agarose gels and then blotted onto
positively charged nylon membranes. Southern and Northern blots were
hybridized in ExpressHyb hybridization solution
(CLONTECH, Palo Alto, CA) for 2 h at 60 °C,
followed by low- and high-stringency washes as described (28). The
full-length cDNA of pBD-1 and the 198-bp cDNA
fragment of
-actin were labeled randomly with 32P and
used as probes. A 452-bp glyceraldehyde-3-phosphate dehydrogenase cDNA probe, generated by PCR with primers 5'-ACC ACA GTC CAT GCC ATC AC-3' (sense) and 5'-TCC ACC ACC CTG TTG CTG-3' (antisense), was
used as the internal control in Northern blots.
Plasmid and Cell Transfection--
A 1466-bp pBD-1
promoter, which contained the 1384-bp sequence upstream of the
pBD-1 transcription initiation site and the 82-bp complete
exon 1 sequence, was constructed by PCR amplification from the positive
pBluescript plasmid using primers 5'-CCG CTC GAG GGT CTG GAT AAC TCG
GCT-3' (sense) and 5'-CCC AAG CTT CTG GCA CAG GTA ACA GGA C-3'
(antisense). The XhoI and HindIII restriction sites were introduced at the 5'-ends of the sense and antisense primers, respectively. The subsequent PCR product was digested with
HindIII and XhoI and then fused with a luciferase
reporter gene in the pGL3-Basic vector (Promega). The presence of the
correct insert was confirmed by direct sequencing and restriction
digestion. For transfection, the plasmid was purified, and endotoxin
was removed with an EndoFree plasmid purification kit (QIAGEN Inc.). The pNF-
B-Luc vector (CLONTECH), which contains
four tandem copies of the NF-
B response element fused with the
herpes simplex virus thymidine kinase minimal promoter and the
luciferase reporter gene, was transfected as a positive control.
Murine embryonic fibroblast NIH/3T3 cells were obtained from the
American Tissue Culture Collection (Manassas, VA), expanded, and
maintained in Dulbecco's modified Eagle's medium supplemented with
10% low-endotoxin fetal bovine serum. Cells were seeded in 24-well
tissue culture plates and grown to 60-80% confluence before transfection. One µg of plasmid DNA containing the pBD-1
promoter was introduced into each well using 3 µl of Transfast
transfection reagent (Promega) in 200 µl of serum-free medium in
triplicate following the manufacturer's instructions. The pNF-
B-Luc
vector (0.5 µg/well) also was transfected into cells separately.
Following 1 h of incubation, 1 ml of serum-free Dulbecco's
modified Eagle's medium was added to each well. All cells were
incubated for 24 h after transfection, followed by stimulation
with LPS (1 and 10 µg/ml) and/or IL-1
(10 ng/ml) for another
6 h. Luciferase activity was measured in cellular extracts using
the luciferase assay system (Promega). Data were normalized against the
protein concentration of each cellular extract, which was measured by the micro BCA protein assay reagent (Pierce).
 |
RESULTS |
Isolation of the pBD-1 Gene and Its Genomic Sequence--
After
two rounds of PCR using gene-specific primers, two positive clones,
designated 838 and 221, were identified from a total of 103,448 clones
from the porcine BAC genomic library. Southern blot analysis of
digested genomic DNA and both BAC clones, probed with the full-length
pBD-1 cDNA, showed the same restriction pattern with
only one or two bands with each of four restriction enzymes (Fig.
2). These findings suggested that both
BAC clones contained the entire pBD-1 gene and that
pBD-1 is a single-copy gene. An oligonucleotide from the
5'-end of the pBD-1 cDNA hybridized to only one of the
two bands in EcoRI-, PstI-, and
BamHI-digested DNAs (Fig. 2C), indicating that
the other band contained the exon 2 sequence. A 3769-bp sequence of the
gene for pBD-1 was determined and deposited in
GenBankTM. Comparison of this sequence with the
pBD-1 cDNA indicated that the pBD-1 gene is
composed of two short exons interrupted by a 1535-bp intron (Fig.
3A). Exon 1 encodes the
5'-untranslated region and signal sequence of the prepro-pBD-1 peptide,
and exon 2 encodes the pro- and mature sequences as well as the
3'-untranslated region of the pBD-1 peptide (Fig. 3A).
Primer extension revealed a major product of 82 nucleotides (Fig.
4), suggesting that transcription of the
pBD-1 gene was initiated primarily from thymine, which was
assigned as nucleotide +1 (Fig. 3B).

View larger version (58K):
[in this window]
[in a new window]
|
Fig. 2.
Southern blot analysis of the
pBD-1 gene. Ten µg of porcine genomic DNA
(A) or a BAC DNA containing the pBD-1 gene
(B and C) were digested with restriction
endonucleases and size-fractionated by agarose gel electrophoresis. DNA
was transferred to positively charged nylon membranes and then
hybridized with full-length pBD-1 cDNA (A and
B) or the oligonucleotide from the 5'-end of the
pBD-1 cDNA (C), which is the same as used in
the primer extension experiment (see "Experimental Procedures").
P, PstI; E, EcoRI;
H, HindIII; B, BamHI. The
numbers on left indicate size standards in kb.
|
|

View larger version (75K):
[in this window]
[in a new window]
|
Fig. 3.
Structure of the pBD-1
gene. A, structural organization of the
pBD-1 gene and schematic drawing of the pBD-1
cDNA as well as its encoded precursor peptide. The pBD-1
gene contains two short exons interrupted by a large intron with a
short interspersed nuclear element sequence between positions +1972 and
+2108. The prepro-pBD-1 peptide is composed of a signal sequence, a
proregion, and a mature peptide with antibacterial activity.
E, EcoRI; P, PstI,
B, BamHI; SINE, short interspersed
nuclear element; UTR, untranslated region. B, a
1466-bp promoter sequence of the pBD-1 gene. This fragment
was used in the transfection studies, except for the intron sequence.
The sequence is numbered based on the primer extension results (see
Fig. 4), with the transcription start site numbered as +1. Exon 1 sequence is shown in uppercase letters; the start codon is
in boldface; and the TATA box is indicated. C,
comparison of the core promoter sequence of pBD-1 with those
of inducible -defensins. The TATA box as well as NF- B and NF-IL-6
recognition sites are boxed. Dashes were
introduced to maximize the alignment, and exon sequences are shown in
uppercase letters. Besides the TATA box, the consensus
binding sites for NF- B and NF-IL-6 are fairly conserved in the genes
for TAP, enteric -defensin, and human BD-2, but are
absent in the pBD-1 gene.
|
|

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 4.
Primer extension of pBD-1
mRNA. Three µg of tongue epithelial mRNA were
annealed to a pBD-1-specific oligonucleotide,
reverse-transcribed, and then subjected to urea-6% polyacrylamide gel
electrophoresis and autoradiography. A DNA dideoxynucleotide
termination DNA sequence ladder was used as the size standard on the
left. A major product is 82 nucleotides (nt) in
length.
|
|
A 1384-bp fragment upstream from the pBD-1 gene
transcription initiation site was scanned for the presence of consensus
binding sites for known transcription factors using the Findpatterns
program (Genetics Computer Group, Madison, WI). Somewhat to our
surprise, no consensus binding sites for NF-
B or NF-IL-6 were found
in the promoter region of the pBD-1 gene, distinguishing it
from other inducible epithelial
-defensins (Fig. 3C). A
search of the non-redundant GenBankTM gene data base using
the gapped BLASTN program with the entire pBD-1 gene
sequence identified at positions +1972 to +2108 of the intron a short
interspersed nuclear element sequence, which is a repetitive DNA
sequence in the genomes of many mammalian species (50-52).
Interestingly, TAP and enteric
-defensin genes also contained a
highly repetitive Alu sequence in their promoter and intron regions
(35, 40). However, the regulatory role of these repetitive elements
remains unclear. No other matches were notable except for some homology
in the exon regions to several
-defensins.
Chromosomal Localization of the pBD-1 Gene--
Two BAC clones
that contained the pBD-1 gene were used to map the
pBD-1 gene on porcine chromosomes. Based on an inspection of
>100 metaphase chromosome spreads, the pBD-1 gene was
demonstrated to be localized on S. scrofa chromosome 15 at
15q14-q15.1 (Fig. 5A).
In situ hybridization was also performed simultaneously with both BAC clones 838 and 221 and revealed that they could not be distinguished from each other on chromosome 15, suggesting that both
clones reside at the same location (data not shown). To confirm the
relative position of the pBD-1 gene on chromosome 15, two-color FISH was performed using BAC clone 838 for pBD-1
and another BAC DNA for SW919 (Fig. 5B). SW919 is a United
States Department of Agriculture Meat Animal Research Center marker for
S. scrofa chromosome 15 and was assigned to S. scrofa chromosome
15q13.1-q13.2.3 As shown in
Fig. 5B, both BAC clones were colocalized on the same
chromosome in close proximity, and the pBD-1 gene
(green) was relatively telomeric to SW919
(red).

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 5.
Chromosomal mapping of the pBD-1
gene. Chromosomal fluorescence in situ
hybridization mapped the pBD-1 gene to chromosome 15 at
15q14-q15.1. Arrows indicate the hybridization signals.
A, biotin-labeled BAC DNA containing the pBD-1
gene was hybridized to metaphase chromosome spreads and then detected
with fluorescein isothiocyanate-labeled streptavidin and biotinylated
anti-streptavidin antibody. B, a two-color FISH was also
performed using a biotin-labeled pBD-1 BAC DNA and a
digoxigenin-labeled BAC DNA for SW919, which is a United States
Department of Agriculture Meat Animal Research Center marker for
porcine chromosome 15. After hybridization, the probes were detected
with rhodamine-labeled anti-digoxigenin antibody and fluorescein
isothiocyanate-labeled streptavidin/biotinylated anti-streptavidin
antibody. Specific signals for pBD-1 and SW919 are in
green and red, respectively. Results are
representative of >100 metaphase chromosome spreads examined.
|
|
pBD-1 Gene Is Expressed Constitutively during Inflammation and
Infection--
Because no consensus binding sites for NF-
B and
NF-IL-6 were found in the promoter region of the pBD-1 gene,
we conducted in vitro and in vivo challenge
studies to evaluate the inducibility of this gene. We first stimulated
in vitro primary porcine tongue epithelial cells, where the
pBD-1 mRNA could be detected easily by Northern blot
analysis. As shown in Fig. 6, the
pBD-1 mRNA was expressed abundantly in resting porcine
tongue epithelia. However, stimulation of the cells with LPS (0.1 and 1 µg/ml), TNF-
(10 ng/ml), IL-1
(10 ng/ml), or a combination of
the three proinflammatory mediators failed to further up-regulate the
expression of the pBD-1 gene at 9 h (Fig. 6) or 16 h (data not shown) post-challenge. Because of the paucity of
information on inducible genes in porcine tongue epithelia, it is not
possible to disregard experimental procedure as the reason for the lack
of up-regulation of pBD-1. However, electrophoretic mobility
shift assays have shown the nuclear translocation of NF-
B in these
cells when stimulated with
LPS.4

View larger version (77K):
[in this window]
[in a new window]
|
Fig. 6.
Northern analysis of the pBD-1
mRNA expression in tongue epithelial cells. Primary
porcine tongue epithelial cells were scraped from the dorsal side of
tongues and cultured for 9 h in the presence or absence of
stimulants. Total RNA was isolated and subjected to Northern analysis
(10 µg/lane) and simultaneously hybridized with cDNA probes for
both pBD-1 and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Lane 1, no LPS; lane 2, 100 ng/ml LPS; lane 3, 1 µg/ml LPS; lane 4, 10 ng/ml TNF- ; lane 5, 10 ng/ml IL-1 ; lane 6,
100 ng/ml LPS + 10 ng/ml TNF- + 10 ng/ml IL-1 . Similar results
were obtained using tongue epithelial cells from two different
pigs.
|
|
The constitutive expression of the pBD-1 mRNA during
infection was also confirmed by two in vivo bacterial
challenge studies. We experimentally infected 6-8-week-old healthy
pigs either with 109 colony-forming units of an enteric
disease-causing bacterium, S. typhimurium, or with 5 × 108 colony-forming units of a respiratory disease-causing
bacterium, A. pleuropneumoniae. Typical clinical signs of
salmonellosis or pneumonia, including fever and diarrhea, were observed
6-12 h following oral or intranasal infection with S. typhimurium or A. pleuropneumoniae, but not in control
pigs, which were mock-challenged with growth medium alone. Epithelial
tissues from intestine or trachea were sampled from each of the control
and infected pigs at various times following infection. The expression
of pBD-1 mRNA was not increased in jejunum (Fig.
7A), colon (data not shown), or tracheal epithelia (Fig. 7B) at any time examined during
a period of 2 days.

View larger version (89K):
[in this window]
[in a new window]
|
Fig. 7.
Reverse transcriptase-PCR analysis of the
pBD-1 mRNA expression in infected tissues.
Epithelial tissues from S. typhimurium-challenged jejunum
(A) and A. pleuropneumoniae-challenged trachea
(B) were scraped and used for RNA isolation from either
control (CON) or infected pigs (see "Experimental
Procedures" for challenge protocols). One µg of total RNA was used
in reverse transcriptase-PCR, and the subsequent PCR product (10 µl)
was subjected to Southern analysis. Twenty-six cycles were used in PCR
for pBD-1 and 16 cycles for -actin. Results are representative of
two replicates of three to four pigs/time point.
|
|
We also performed 3'-rapid amplification of cDNA ends using normal
and bacteria-challenged epithelial tissues from tongue, colon, and
trachea as described (28). A degenerate upstream primer, 5'-ATG AG(A/G)
CTC CA(C/T) C(A/G)C CT(C/G) CTC CT-3', was designed based on the highly
conserved region in the signal sequences of porcine, bovine, and sheep
-defensins. This would allow identification of possible isoforms of
porcine
-defensins. However, only the pBD-1 cDNA
sequence was found after sequencing eight independent plasmid clones
derived from each of the above epithelial tissues.4
Furthermore, Southern hybridization of the rapid amplification of
cDNA ends products from infected tissues with full-length
pBD-1 cDNA revealed signals comparable to those of
normal tissues. These data suggest that, in contrast to humans and
cattle, pigs have no inducible isoforms of epithelial
-defensins and
that the pBD-1 gene is likely to be the only epithelial
-defensin present.
PBD-1 Gene Promoter Has No Inducible Activity--
To directly
test if pBD-1 gene expression could be modulated by
proinflammatory agents, transient transfections were performed using a
1466-bp pBD-1 promoter-luciferase construct. This promoter contained a 1384-bp sequence upstream of the pBD-1 gene
transcription initiation site and the 82-bp complete exon 1 sequence
(Fig. 3B), where several consensus NF-
B- and
NF-IL-6-binding sites were generally conserved in other inducible
epithelial
-defensins (Fig. 3C). Compared with the
negative control, transfection of murine fibroblast NIH/3T3 cells with
the pNF-
B-Luc vector resulted in 5-8-fold increases in luciferase
activity when cells were stimulated with LPS and/or IL-1
for 6 h (Fig. 8A). However,
stimulation of the cells with up to 10 µg/ml LPS, 10 ng/ml IL-1
,
or a combination of these two agents for 6 h failed to further
enhance the expression of the reporter gene under the control of the
1466-bp pBD-1 promoter (Fig. 8B), suggesting that
the pBD-1 promoter has little or no inducible activity in
response to proinflammatory signals. This finding was also consistent
with our in vivo and in vitro challenge data
(Figs. 6 and 7).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 8.
The pBD-1 gene promoter has
no inducible activity in response to LPS and
IL-1 . The 1466-bp pBD-1
promoter, which contained a 1384-bp sequence upstream of the
pBD-1 transcription initiation site and the 82-bp complete
exon 1 sequence, was ligated into a luciferase reporter vector
(pGL3-Basic). NIH/3T3 cells were transfected with a 0.5 µg/well
concentration of the pNF- B-Luc vector (A) or with a 1 µg/well concentration of plasmid DNA containing the pBD-1
promoter (B) in 200 µl of serum-free medium in triplicate.
Serum-free medium (1 ml) was added to each well following 1 h of
incubation. All cells were cultured for 24 h after transfection,
followed by stimulation with 1 or 10 µg/ml LPS, 10 ng/ml IL-1 , or
a combination of 10 µg/ml LPS and 10 ng/ml IL-1 for another
6 h. Luciferase activity was measured in cellular extracts and
then normalized against the protein concentration of each
cellular extract. Values are means ± S.D. of three wells. Similar
results were obtained from three independent experiments.
|
|
 |
DISCUSSION |
Skin and epithelial tissues are exposed continuously to a variety
of microorganisms and thus provide the first line of defense between
the host and the environment (53, 54). Disruption of this barrier
commonly leads to microbial invasion and subsequent inflammation and
infection. Indeed, skin and mucosa not only serve as physical barriers,
but also produce a vast array of endogenous peptide antibiotics,
including two major types, namely cathelicidins (55, 56) and
-defensins (2, 3, 11).
Human LL-37/CAP-18 is the only cathelicidin that has been found to be
produced by skin keratinocytes and lung epithelia in response to injury
or infection (23, 57). In contrast,
-defensins are the best
characterized epithelium-derived peptide antibiotics and many have been
implicated in mucosal immunity (11). To date, most
-defensins in
humans, mice, cattle, sheep, and pigs have been shown to be expressed
by either skin keratinocytes or epithelial cells throughout the
respiratory, digestive, and urogenital tracts.
These epithelial
-defensins have been classified into two groups
based on the differences in homology of amino acid sequences, gene
structure, and the sites of expression (11, 26). As shown with
epithelial
-defensins of humans, mice, and cattle, TAP-like genes
are up-regulated in response to infectious or inflammatory agents (12,
35-41), whereas human BD-1-like genes have a constitutive expression pattern regardless of inflammation or infection (17, 28, 31,
33). Based on its amino acid sequence, pBD-1 could be placed
into the group of TAP-like genes with an expected inducible expression
pattern. However, several independent lines of evidence indicated that
the pBD-1 gene was not up-regulated in response to
inflammatory mediators or during infectious states. This finding may
reflect interspecies variation, which is observed commonly in gene
families of many peptide antibiotics. The pBD-1 gene appears to be the only example, examined to date, that is contrary to the
current classification in that it exhibits a constitutive expression
pattern, although resembling TAP-like genes. Thus, classification and
generalization of epithelial
-defensins must be made with caution,
and more precise grouping awaits the identification and
characterization of more family members.
In our studies, stimulation of porcine tongue epithelial cells with
LPS, TNF-
, and IL-1
did not enhance the expression of the
pBD-1 mRNA. These agents are all potent inflammatory
mediators and are encountered commonly by epithelial cells of the oral
or airway mucosa. Following experimental infections with either
S. typhimurium or A. pleuropneumoniae, pigs
failed to increase pBD-1 gene expression to counteract the
bacterial invasions into the intestinal or tracheal mucosa. These
findings are in agreement with our previous data showing no increase in
pBD-1 protein after porcine tongue was subjected to localized
microinjury (42). Scanning the promoter region of the pBD-1
gene revealed a lack of consensus binding sites for NF-
B and
NF-IL-6, which are major transcription factors involved in the
acute-phase response and inflammation (58-61) and also have been
demonstrated to be rather well conserved in other inducible epithelial
-defensins. Consistent with this observation, direct transfection of
a 1.4-kb pBD-1 gene promoter showed no difference in the
reporter gene activity in response to challenge with up to 10 µg/ml
LPS.
Our physical localization of the pBD-1 gene to S. scrofa chromosome 15q14-q15.1 provides support for previous
ZOO-FISH data indicating that a narrow region of H. sapiens
chromosome 8 corresponds to S. scrofa chromosome q15 (43,
44). Moreover, it adds valuable information to the comparative map by
providing the first direct evidence that H. sapiens
chromosome 8p23, the location of human
- and
-defensin genes
(12-15), is homologous to this region of S. scrofa
chromosome 15. Thus, it provides an entry point for testing whether
other loci on H. sapiens chromosome 8p23 may also map to
this region of S. scrofa chromosome 15.
In summary, we have cloned and characterized an additional gene for
epithelial
-defensins, namely the pBD-1 gene, and have physically mapped it to S. scrofa chromosome 15q14-q15.1.
Although it resembles many inducible epithelial
-defensins in
genomic structure, amino acid sequence, and sites of expression, the
pBD-1 gene is expressed constitutively by epithelia of
porcine tongue, intestine, and trachea during inflammation and
infection. This pattern of expression and disposition of the pBD-1
peptide in airway and oral mucosa suggests that it may play a role in
maintaining the steady state of natural microflora on mucosal surfaces.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Ernie Minton for assistance with
the challenge studies and Dani Goodband and Elena Donskaya for
excellent technical assistance.
 |
FOOTNOTES |
*
This work was supported in part by National Research
Initiative Grants 95-37204-2141 and 98-35204-6397 (to F. B. and
C. R. R.) and 96-35205-3824 (to D. T.) from the United States
Department of Agriculture. This is Contribution 99-398-J of the
Kansas Agricultural Experiment Station.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF132038.
To whom correspondence should be addressed: Dept. of Anatomy
and Physiology, Kansas State University, 1600 Denison Ave., VMS 228, Manhattan, KS 66506. Tel.: 785-532-4537; Fax: 785-532-4557; E-mail:
blecha@vet.ksu.edu.
2
Suzuki, K., Asakawa, S., Iida, M., Shimanuki,
S., Fujishima, N., Hiraiwa, H., Murakami, Y., Shimizu, N., and Yasue,
H. (1999) Anim. Genet., in press.
3
K. Suzuki, M. Iida, S. Shimanuki, H. Hiraiwa, H. Yasue, unpublished data.
4
G. Zhang, C. Ross, and F. Blecha, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
kb, kilobase(s);
bp, base pair(s);
TAP, tracheal antimicrobial peptide;
NF, nuclear factor;
IL, interleukin;
PCR, polymerase chain reaction;
BAC, bacterial
artificial chromosome;
FISH, fluorescence in situ
hybridization;
LPS, lipopolysaccharide;
TNF-
, tumor necrosis
factor-
.
 |
REFERENCES |
| 1.
|
Boman, H.
(1995)
Annu. Rev. Immunol.
13,
61-92[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Martin, E.,
Ganz, T.,
and Lehrer, R. I.
(1995)
J. Leukocyte Biol.
58,
128-136[Abstract]
|
| 3.
|
Lehrer, R. I.,
and Ganz, T.
(1996)
Ann. N. Y. Acad. Sci.
797,
228-239[Medline]
[Order article via Infotrieve]
|
| 4.
|
Ouellette, A. J.,
and Selsted, M. E.
(1996)
FASEB J.
10,
1280-1289[Abstract]
|
| 5.
|
Ganz, T.
(1994)
CIBA Found. Symp.
186,
62-76[Medline]
[Order article via Infotrieve]
|
| 6.
|
Hill, C. P.,
Yee, J.,
Selsted, M. E.,
and Eisenberg, D.
(1991)
Science
251,
1481-1485[Abstract/Free Full Text]
|
| 7.
|
Lichtenstein, A.
(1991)
J. Clin. Invest.
88,
93-100
|
| 8.
|
Wimley, W. C.,
Selsted, M. E.,
and White, S. H.
(1994)
Protein Sci.
3,
1362-1373[Abstract]
|
| 9.
|
White, S. H.,
Wimley, W. C.,
and Selsted, M. E.
(1995)
Curr. Opin. Struct. Biol.
5,
521-527[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Zimmermann, G. R.,
Legault, P.,
Selsted, M. E.,
and Pardi, A.
(1995)
Biochemistry
34,
13663-13671[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Diamond, G.,
and Bevins, C. L.
(1998)
Clin. Immunol. Immunopathol.
88,
221-225[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Liu, L.,
Wang, L.,
Jia, H. P.,
Zhao, C.,
Heng, H. H. Q.,
Schutte, B. C.,
McCray, P. B.,
and Ganz, T.
(1998)
Gene (Amst.)
222,
237-244[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Sparkes, R. S.,
Kronenberg, M.,
Heinzmann, C.,
Daher, K. A.,
Klisak, I.,
Ganz, T.,
and Mohandas, T.
(1989)
Genomics
5,
240-244[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Bevins, C. L.,
Jones, D. E.,
Dutra, A.,
Schaffzin, J.,
and Muenke, M.
(1996)
Genomics
31,
95-106[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Liu, L.,
Zhao, C.,
Heng, H. H. Q.,
and Ganz, T.
(1997)
Genomics
43,
316-320[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Ouellette, A. J.,
Pravtcheva, D.,
Ruddle, F. H.,
and James, M.
(1989)
Genomics
5,
233-239[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Huttner, K. M.,
Kozark, C. A.,
and Bevins, C. L.
(1997)
FEBS Lett.
413,
45-49[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Gallagher, D. S.,
Ryan, A. M.,
Diamond, G.,
Bevins, C. L.,
and Womack, J. E.
(1995)
Mamm. Genome
6,
554-556[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Iannuzzi, L.,
Gallagher, D. S.,
Di Meo, G. P.,
Diamond, G.,
Bevins, C. L.,
and Womack, J. E.
(1996)
Cytogenet. Cell Genet.
75,
10-13[Medline]
[Order article via Infotrieve]
|
| 20.
|
Huttner, K. M.,
Lambeth, M. R.,
Burkin, H. R.,
Burkin, D. J.,
and Broad, T. E.
(1998)
Gene (Amst.)
206,
85-91[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Smith, J. J.,
Travis, S. M.,
Greenberg, E. P.,
and Welsh, M. J.
(1996)
Cell
85,
229-236[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Goldman, M. J.,
Anderson, G. M.,
Stozenberg, E. D.,
Kari, U. P.,
Zasloff, M.,
and Wilson, J. M.
(1997)
Cell
88,
553-560[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Bals, R.,
Wang, X.,
Zasloff, M.,
and Wilson, J. M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
9541-9546[Abstract/Free Full Text]
|
| 24.
|
Bals, R.,
Wang, X.,
Wu, Z.,
Freeman, T.,
Bafna, V.,
Zasloff, M.,
and Wilson, J. M.
(1998)
J. Clin. Invest.
102,
874-880[Medline]
[Order article via Infotrieve]
|
| 25.
|
Singh, P. K.,
Jia, H. P.,
Wiles, K.,
Hesselberth, J.,
Liu, L.,
Conway, B. A. D.,
Greenberg, E. P.,
Valore, E. V.,
Welsh, M. J.,
Ganz, T.,
Tack, B. F.,
and McCray, P. B.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
14961-14966[Abstract/Free Full Text]
|
| 26.
|
Zhang, G.,
Wu, H.,
Shi, J.,
Ganz, T.,
Ross, C. R.,
and Blecha, F.
(1998)
FEBS Lett.
424,
37-40[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Bensch, K. W.,
Raida, M.,
Magert, H.-J.,
Schulz-Knappe, P.,
and Forssmann, W.-G.
(1995)
FEBS Lett.
368,
331-335[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Zhao, C.,
Wang, I.,
and Lehrer, R. I.
(1996)
FEBS Lett.
396,
319-322[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
McCray, P. B.,
and Bentley, L.
(1997)
Am. J. Respir. Cell Mol. Biol.
16,
343-349[Abstract]
|
| 30.
|
Fulton, C.,
Anderson, G. M.,
Zasloff, M.,
Bull, R.,
and Quinn, A. G.
(1997)
Lancet
350,
1750-1751[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Valore, E. V.,
Park, C. H.,
Quayle, A. J.,
Wiles, K. R.,
McCray, P. B.,
and Ganz, T.
(1998)
J. Clin. Invest.
101,
1633-1642[Medline]
[Order article via Infotrieve]
|
| 32.
|
Krisanaprakornkit, S.,
Weinberg, A.,
Perez, C. N.,
and Dale, B. A.
(1998)
Infect. Immun.
66,
4222-4228[Abstract/Free Full Text]
|
| 33.
|
Bals, R.,
Goldman, M. J.,
and Wilson, J. M.
(1998)
Infect. Immun.
66,
1225-1232[Abstract/Free Full Text]
|
| 34.
|
Diamond, G.,
Zasloff, M. A.,
Eck, H.,
Brasseur, M.,
Maloy, W. L.,
and Bevins, C. L.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
3952-3956[Abstract/Free Full Text]
|
| 35.
|
Diamond, G.,
Jones, D. E.,
and Bevins, C. L.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
4596-4600[Abstract/Free Full Text]
|
| 36.
|
Diamond, G.,
Russell, J. P.,
and Bevins, C. L.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
5156-5160[Abstract/Free Full Text]
|
| 37.
|
Russell, J. P.,
Diamond, G.,
Tarver, A. P.,
Scanlin, T. F.,
and Bevins, C. L.
(1996)
Infect. Immun.
64,
1565-1568[Abstract]
|
| 38.
|
Schonwetter, B. S.,
Stolzenberg, E. D.,
and Zasloff, M. A.
(1995)
Science
267,
1645-1648[Abstract/Free Full Text]
|
| 39.
|
Stolzenberg, E. D.,
Anderson, G. M.,
Ackermann, M. R.,
Whitlock, R. H.,
and Zasloff, M. A.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
8686-8690[Abstract/Free Full Text]
|
| 40.
|
Tarver, A. P.,
Clark, D. P.,
Diamond, G.,
Russell, J. P.,
Erdjument-Bromage, H.,
Tempst, P.,
Cohen, K. S.,
Jones, D. E.,
Sweeney, R. W.,
Wines, M.,
Hwang, S.,
and Bevins, C. L.
(1998)
Infect. Immun.
66,
1045-1056[Abstract/Free Full Text]
|
| 41.
|
Harder, J.,
Bartels, J.,
Christophers, E.,
and Schroder, J. M.
(1997)
Nature
387,
861[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Shi, J.,
Zhang, G.,
Wu, H.,
Ross, C.,
Blecha, F.,
and Ganz, T.
(1999)
Infect. Immun.
67,
3121-3127[Abstract/Free Full Text]
|
| 43.
|
Goureau, A.,
Yerle, M.,
Schmitz, A.,
Riquet, J.,
Milan, D.,
Pinton, P.,
Frelat, G.,
and Gellin, J.
(1996)
Genomics
36,
252-262[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Fronicke, L. F.,
Chowdhary, B. P.,
Scherthan, H.,
and Gustavsson, I.
(1996)
Mamm. Genome
7,
285-290[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Asakawa, S.,
Abe, I.,
Kudoh, Y.,
Kishi, N.,
Wang, Y.,
Kubota, R.,
Kudoh, J.,
Kawasaki, K.,
Minoshima, S.,
and Shimizu, N.
(1997)
Gene (Amst.)
191,
69-79[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 47.
|
Yasue, H.,
Kusumoto, H.,
and Mikami, H.
(1995)
Cytogenet. Cell Genet.
71,
249-252[Medline]
[Order article via Infotrieve]
|
| 48.
| Yasue, H., Hisamatsu, N., Awata, T., Wada, Y., and Kusumoto, H. (1999)
Anim. Genet., in press
|
| 49.
|
George, C. P.,
and Kadonaga, J. T.
(1996)
in
A Laboratory Guide to RNA: Isolation, Analysis, and Synthesis
(Kreig, P. A., ed)
, pp. 133-139, Wiley-Liss, Inc., New York
|
| 50.
|
Singer, D. S.,
Parent, L. J.,
and Ehrlich, R.
(1987)
Nucleic Acids Res.
15,
2780[Free Full Text]
|
| 51.
|
Korenberg, J. R.,
and Rykowski, M. C.
(1988)
Cell
53,
391-400[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Frengen, E.,
Thomsen, P.,
Kristensen, T.,
Kran, S.,
Miller, R.,
and Davis, W.
(1991)
Genomics
10,
949-956[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Weinberg, A.,
Krisanaprakornkit, S.,
and Dale, B. A.
(1998)
Crit. Rev. Oral Biol. Med.
9,
399-414[Abstract/Free Full Text]
|
| 54.
|
Gallo, R. L.,
and Huttner, K. M.
(1998)
J. Invest. Dermatol.
111,
739-743[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Zanetti, M.,
Gennaro, R.,
and Romeo, D.
(1995)
FEBS Lett.
374,
1-5[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Zanetti, M.,
Gennaro, R.,
and Romeo, D.
(1997)
Ann. N. Y. Acad. Sci.
832,
147-162[Medline]
[Order article via Infotrieve]
|
| 57.
|
Frohm, M.,
Agerberth, B.,
Ahangari, G.,
Stahle-Backdahl, M.,
Liden, S.,
Wigzell, H.,
and Gudmundsson, G.-H.
(1997)
J. Biol. Chem.
272,
15258-15263[Abstract/Free Full Text]
|
| 58.
|
Kopp, E. B.,
and Ghost, S.
(1995)
Adv. Immunol.
58,
1-27[Medline]
[Order article via Infotrieve]
|
| 59.
|
Baeuerle, P. A.,
and Baltimore, D.
(1996)
Cell
87,
13-20[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Akira, S.,
Isshiki, H.,
Sugita, T.,
Tanabe, O.,
Kinoshita, S.,
Nishio, Y.,
Nakajima, T.,
Hirano, T.,
and Kishimoto, T.
(1990)
EMBO J.
9,
1897-1906[Medline]
[Order article via Infotrieve]
|
| 61.
|
Akira, S.,
and Kishimoto, T.
(1997)
Adv. Immunol.
65,
1-46[Medline]
[Order article via Infotrieve]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit 